Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JALSG APL212G post-remission arsenic trioxide study in older acute promyelocytic leukemia
jRCTs041180099Phase 2Completed
- Sponsor
- JALSG Supportive Organization
- Start
- Oct 2012
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of arsenic trioxide, tretinoin and tamibarotene in Acute promyelocytic leukaemia (APL), sponsored by JALSG Supportive Organization. Primary endpoint: 3-year event-free survival. Started Oct 2012; status: completed.
02
Drugs
arsenic trioxidetretinointamibarotene
03
Conditions
Acute promyelocytic leukaemia (APL)
Beyond the preview
Go deeper on jRCTs041180099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041180099.